Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5
Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis
Authors Baker S
Published 10 October 2008 Volume 2008:4(5) Pages 1079—1084
DOI https://doi.org/10.2147/TCRM.S3123
Review by Single anonymous peer review
Peer reviewer comments 3
Susan S Baker
Department of Pediatrics, University at Buffalo, Buffalo, NY, USA
Abstract: Pancreatic enzyme replacement therapy (PERT) is the only treatment for malabsorption in cystic fi brosis (CF) caused by pancreatic insufficiency (PI). PI occurs in approximately 85% of patients with CF. PERT overcomes some, but not all the signs and symptoms of malabsorption. Clinical parameters such as growth, abdominal pain, diarrhea and gassiness, commonly used to adjust PERT dosing, are shown not to be good indicators of their effectiveness. The FDA does not provide oversight of preparations of pancreatic enzymes consistent with the oversight it provides for all other drugs. The FDA intends to rectify this situation. Measures of the effectiveness of PERT are limited to the coefficient of fat absorption, a difficult and unpleasant exercise for patients.
Keywords: pancrelipase, cystic fibrosis, malabsorption, pancreatic enzymes
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.